Overviewing Real-World Outcomes to Boost Interventional Management of CAlcified Coronary Lesions: the OROBICA Registry. (OROBICA)
The OROBICA (Overviewing Real-World Outcomes to Boost Interventional Management of CAlcified Coronary Lesions) Registry is a multicenter, ambispective, real-world observational study designed to evaluate clinical, procedural, imaging, and economic outcomes of patients undergoing percutaneous coronary intervention (PCI) for severely calcified coronary artery disease.
Coronary artery calcification represents one of the main determinants of procedural complexity and adverse outcomes in contemporary interventional cardiology. Despite the increasing availability of advanced calcium-modification technologies and intracoronary imaging techniques, evidence regarding the optimal treatment strategy in real-world clinical practice remains limited, particularly among high-risk and complex patients often underrepresented in randomized trials.
The OROBICA Registry aims to systematically collect longitudinal data from all-comer patients treated for severely calcified coronary lesions using contemporary PCI strategies, including intracoronary imaging guidance (IVUS/OCT), rotational atherectomy, orbital atherectomy, intravascular lithotripsy, specialty balloons, and combined calcium-modification approaches.
The primary objective is to assess clinical and procedural outcomes, with particular focus on target vessel failure (TVF). Secondary and exploratory objectives include evaluation of procedural success, imaging findings, predictors of adverse outcomes, healthcare resource utilization, and economic impact associated with the treatment of calcified coronary lesions.
The registry is designed as a flexible research platform intended to support future hypothesis-generating analyses and provide real-world evidence to improve personalized management strategies for calcified coronary artery disease.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Locations
-
-
Bergamo
-
Bergamo, Bergamo, Italy, 24127
- ASST Papa Giovanni XXIII
-
Contact:
- Francesco Moretti, MD
- Phone Number: +39 0352678249
- Email: f.moretti@asst-pg23.it
-
Contact:
- Elena Zattoni, MSc
- Phone Number: +39 0352673452
- Email: zattoni.elena@asst-pg23.it
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients undergoing percutaneous coronary intervention (PCI) for severely calcified coronary lesions, angiographically defined as radiopacities noted without cardiac motion before contrast injection, generally involving both sides of the arterial wall.
Patients undergoing PCI for calcified coronary lesions with intracoronary optical coherence tomography (OCT) showing at least one of the following features:
- calcium arc ≥180°
- calcium thickness ≥0.3 mm
- calcium length ≥3 mm
- presence of calcified nodules
Patients undergoing PCI for calcified coronary lesions with intravascular ultrasound (IVUS) showing at least one of the following features:
- calcium arc ≥180°
- concentric or superficial calcium with extensive acoustic shadowing
- presence of calcified nodules
Exclusion Criteria:
- Lack of availability of essential clinical or procedural data.
- Refusal or withdrawal of informed consent for the prospective component of the registry, when applicable.
- Exercise of the right to object to data processing, according to applicable data protection regulations.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Imaging group
Patients undergoing intravascular imaging-guided PCI
|
In this registry patients will undergo PCI of severely calcified coronary arteries
|
|
Debulking group
Patients undergoing PCI with advanced calcium-modification devices
|
In this registry patients will undergo PCI of severely calcified coronary arteries
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of Target Vessel Failure (TVF)
Time Frame: 1, 2 and 5 years
|
Defined as composite of Cardiac Death, Target vessel Myocardial Infarction and Clinically-Driven Target Vessel Revascularization
|
1, 2 and 5 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of Major Adverse Cardiovascular Events (MACE)
Time Frame: 1, 2 and 5 years
|
Defined as composite of all-cause death, myocardial infarction (MI), stroke, clinically-driven target vessel revascularisation (CD-TVR) and hospitalization for cardiovascular causes
|
1, 2 and 5 years
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of MACE and Repeat Revascularization across Calcium Modification Techniques.
Time Frame: 30 days, 1, 2 and 5 years
|
Evaluation of the incidence of Major Adverse Cardiovascular Events (MACE) and Target Lesion Revascularization (TLR) in relation to the specific calcium modification strategy used: rotational atherectomy, orbital atherectomy, intravascular lithotripsy (IVL), excimer laser, or combined strategies.
|
30 days, 1, 2 and 5 years
|
|
Total Procedural Costs and Healthcare Resource Utilization.
Time Frame: From index procedure up to 12 months.
|
Assessment of total economic burden including costs of specific interventional materials/devices, total procedure duration, length of index hospital stay, and rate of all-cause hospital readmissions.
|
From index procedure up to 12 months.
|
|
Predictors of Severe Coronary Calcification and Procedural Complexity.
Time Frame: Baseline (at the time of index procedure).
|
Identification of clinical, angiographic, intravascular imaging, and biochemical markers (e.g., renal function, calcium-phosphorus metabolism) associated with the presence of severe calcification and the requirement for advanced calcium modification tools.
|
Baseline (at the time of index procedure).
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Francesco Moretti, MD, Papa Giovanni XXIII Hospital, Bergamo
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Vascular Diseases
- Cardiovascular Diseases
- Heart Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Coronary Disease
- Myocardial Ischemia
- Coronary Artery Disease
- Surgical Procedures, Operative
- Endovascular Procedures
- Vascular Surgical Procedures
- Cardiovascular Surgical Procedures
- Minimally Invasive Surgical Procedures
- Percutaneous Coronary Intervention
Other Study ID Numbers
Other Study ID Numbers
- OROBICA-2026-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Percutaneous Coronary Intervention
-
NCT00870038UnknownTo Achieve an Early Reendothelialization at the Expense of Low Restenosis: The EREMUS Study (EREMUS)Percutaneous Coronary Intervention | Angioplasty, Transluminal, Percutaneous Coronary
-
NCT05340998CompletedPercutaneous Coronary Intervention | Coronary Angiography
-
NCT06502938Not yet recruitingPercutaneous Coronary Intervention
-
NCT03809273CompletedPercutaneous Coronary Intervention
-
NCT04103086UnknownPercutaneous Coronary Intervention
-
NCT04047199UnknownPercutaneous Coronary Intervention
-
NCT02691819UnknownPercutaneous Coronary Intervention
-
NCT07629037Not yet recruitingPercutaneous Coronary Intervention
-
NCT05981859CompletedPercutaneous Coronary Intervention
-
NCT00751231CompletedPercutaneous Coronary Intervention
Clinical Trials on Percutaneous coronary intervention with or without stent implantation
-
NCT02272283CompletedMyocardial Infarction | Coronary Artery Disease
-
NCT06131333CompletedComplex Coronary Artery Disease
-
NCT04738344WithdrawnCoronary Artery Disease | Chronic Coronary Syndrome | Drug Eluting Stents
-
NCT01149044CompletedST Elevation Myocardial Infarction | Acute Coronary Syndrome | Percutaneous Coronary Intervention
-
NCT01466634CompletedMyocardial Infarction | Restenosis
-
NCT00300157CompletedCoronary Arteriosclerosis
-
NCT04085614CompletedCoronary Artery Disease
-
NCT06475625Active, not recruitingCoronary Artery Disease | Chronic Kidney Diseases
-
NCT03548272UnknownCoronary Artery Disease